论文部分内容阅读
在实验室条件下以抗坏血酸（Ｖｃ）、硬脂酸酯为原料研制合成了一种新型抗氧化剂抗坏血酸脂肪酸酯（ＡＳ）样品，并经红外光谱测定等检测手段确认其为ＡＳ。用ＡＳ样品进行细胞微核实验和Ａｍｅｓ实验，结果表明：（１）ＡＳ可降低ＣＰ诱发的小鼠活体骨髓细胞的微核率，并且其剂量与抑制率之间存在剂量－反应关系，因而说明其具有抗致突变作用。（２）ＡＳ和Ｖｃ一样对ＴＡ００、ＴＡ９８具有抗诱变作用，并且其剂量与抑制率之间存在着剂量－效应关系。（３）相同当量浓度下ＡＳ的抑制作用较Ｖｃ强，因此，认为ＡＳ抗诱变作用有可能较它自身的Ｖｃ生物活性作用强。实验证明ＡＳ具有抗诱变作用，并且其抗诱变作用有可能较其自身的Ｖｃ生物活性强。
A new antioxidant ascorbic acid fatty acid ester (AS) was synthesized from ascorbic acid (Vc) and stearic acid ester under laboratory conditions and was identified as AS by means of infrared spectroscopy. AS samples were used for micronucleus test and Ames test. The results showed that: (1) AS can reduce the micronucleus rate of CP-induced mouse live bone marrow cells, and there is a dose-response relationship between dose and inhibition rate, indicating that It has anti-mutagenic effects. (2) AS and Vc have the same anti-mutagenic effects on TA00 and TA98, and there is a dose-response relationship between the dose and the inhibition rate. (3) The inhibitory effect of AS at the same equivalent concentration is stronger than that of Vc, therefore, it is considered that the anti-mutagenic effect of AS may be stronger than its own Vc biological activity. Experiments show that AS has an anti-mutagenic effect, and its anti-mutagenic effect may be stronger than its own Vc biological activity.